The NoSAS score: A new and simple screening tool for obstructive sleep apnea syndrome in depressive disorder.
Journal of Affective Disorders. 2018-02-01; 227: 136-140
DOI: 10.1016/j.jad.2017.10.015
Read on PubMed
1. J Affect Disord. 2018 Feb;227:136-140. doi: 10.1016/j.jad.2017.10.015. Epub 2017
Oct 5.
The NoSAS score: A new and simple screening tool for obstructive sleep apnea
syndrome in depressive disorder.
Guichard K(1), Marti-Soler H(2), Micoulaud-Franchi JA(3), Philip P(3),
Marques-Vidal P(4), Vollenweider P(4), Waeber G(4), Preisig M(5), Haba-Rubio
J(2), Heinzer R(6).
Author information:
(1)Center for Investigation and Research in Sleep (CIRS), Lausanne University
Hospital (CHUV), Lausanne, Switzerland; CNRS, SANPSY, USR 3413, F-33000 Bordeaux,
France; Université de Bordeaux, SANPSY, USR 3413, F-33000 Bordeaux, France;
Clinique du Sommeil, Bordeaux University Hospital (CHU), Bordeaux, France.
(2)Center for Investigation and Research in Sleep (CIRS), Lausanne University
Hospital (CHUV), Lausanne, Switzerland.
(3)CNRS, SANPSY, USR 3413, F-33000 Bordeaux, France; Université de Bordeaux,
SANPSY, USR 3413, F-33000 Bordeaux, France; Clinique du Sommeil, Bordeaux
University Hospital (CHU), Bordeaux, France.
(4)Department of Internal Medicine, Lausanne University Hospital (CHUV),
Lausanne, Switzerland.
(5)Department of Psychiatry, Lausanne University Hospital (CHUV), Lausanne,
Switzerland.
(6)Center for Investigation and Research in Sleep (CIRS), Lausanne University
Hospital (CHUV), Lausanne, Switzerland. Electronic address:
.
BACKGROUND: Since the clinical presentation of obstructive sleep apnea syndrome
(OSAS) shares common features with major depressive (MDE), the screening of OSAS
is challenging in this population. The aim of this study was to assess the
effectiveness of the NoSAS score in predicting the presence of OSAS among
participants with current MDE and to compare it with the performance of existing
screening tools.
METHODS: A random sample of the population-based cohort CoLaus (Lausanne,
Switzerland) underwent a psychiatric evaluation (PsyCoLaus) and a complete
polysomnography at home (HypnoLaus). The effectiveness of the NoSAS score in
detecting the risk of significant OSAS among current MDE participants was
assessed and compared with STOP-BANG and Berlin scores.
RESULTS: Among the 1761 subjects (58,75 ± 11y.o.; 47,8%men) who underwent
polysomnography, significant OSAS was present in 24.0% with and 26.1% without
current MDE. Using a threshold of ≥ 8 points, the NoSAS score identified OSAS in
MDE participants with a sensitivity of 0.79, a specificity of 0.66, a negative
predictive value of 0.91, and a positive predictive value of 0.41. The area under
the ROC curve was 0.72 for NoSAS, 0.66 for STOP-BANG and 0.69 for the Berlin
score (NS).
LIMITATIONS: Only 44% of the PsyCoLaus participants had a polysomnography. The
studied population was mainly of Caucasian ancestry and above 40 years of age.
CONCLUSIONS: This is the first study assessing the performance of screening tools
for OSAS in MDE. The NoSAS score is a simple and efficient screening tool for
OSAS in this population, and may be a helpful instrument for clinicians.
Copyright © 2017 Elsevier B.V. All rights reserved.
DOI: 10.1016/j.jad.2017.10.015
PMID: 29055261